• Liproxstatin-1: Practical Ferroptosis Assays

  2026-09-18

  Learn how Liproxstatin-1, SKU B4987, can improve interpretation of viability, lipid-peroxidation, and ferroptosis experiments. This scenario-based guide covers assay controls, GPX4-deficient cell protection, formulation, cross-domain applications, and practical product selection.

• SR-202 (PPAR antagonist): Assay Reliability

  2026-09-17

  Learn how SR-202 (PPAR antagonist), SKU B6929, can strengthen interpretation of viability, proliferation, adipogenesis, and immunometabolic assays. This scenario-based guide covers mechanism, controls, preparation, data interpretation, and practical product-selection criteria.

• Abaloparatide and FAK Drive Alveolar Bone Augmentation

  2026-09-17

  The 2025 International Journal of Oral Science study shows that local abaloparatide combined with mechanical force can thicken alveolar bone through periosteal osteogenesis. Multi-level evidence implicates focal adhesion kinase as a central mediator, while also highlighting how local delivery may complement existing approaches to periodontal and orthodontic bone support.

• HHV-7 DNA in Ocular Toxoplasmosis: Key Findings

  2026-09-16

  Miyase et al. report the first vitreous-fluid detection of human herpesvirus 7 DNA in a patient with recurrent ocular toxoplasmosis, alongside Toxoplasma gondii DNA. The case shows how compartment-specific multiplex PCR can refine diagnosis in treatment-refractory uveitis, while also illustrating why viral DNA detection alone does not establish causality or active replication.

• Epinephrine Bitartrate: Assay Workflows

  2026-09-16

  Epinephrine Bitartrate provides a practical way to model coordinated α- and β-adrenergic responses in cell, cardiovascular, neurobiology, and sympathetic nervous system studies. This guide translates receptor pharmacology and local-anesthesia evidence into concentration-selection, exposure, control, and troubleshooting decisions for reproducible bench workflows.

• Tamoxifen: Exposure-Aware Research Design

  2026-09-15

  Tamoxifen is a selective estrogen receptor modulator with applications spanning breast cancer research and CreER-mediated gene knockout. This evidence-led guide explains how dose, timing, tissue context, and off-target developmental effects should shape experimental design.

• Halazone and Sodium Current Inactivation in Frog Nerves

  2026-09-15

  The reference study shows that Halazone and hypochlorous acid strongly disrupt sodium-current inactivation in voltage-clamped frog myelinated nerve fibers, whereas several other oxidants mainly shift the voltage dependence of inactivation. Its comparative reagent design argues against a critical role for methionine and instead raises membrane-lipid modification as a tentative explanation.

• CCT007093: PPM1D Inhibitor Workflows

  2026-09-14

  CCT007093 is a practical PPM1D inhibitor for connecting phosphatase control to P38 kinase activation, breast cancer cell cytotoxicity, and renal inflammatory injury. This guide translates its biochemical and cellular evidence into assay workflows, controls, formulation strategies, and troubleshooting decisions.

• GANT61: A Practical GLI Inhibitor Workflow

  2026-09-14

  GANT61 helps researchers test how GLI1/2 activity controls tumor-cell proliferation, pathway output, and immune-evasive signaling. This workflow connects concentration optimization and formulation control with compartment-aware assays inspired by recent GLI2–WNT–prostaglandin findings.

• Halazone Workflows for Water and Ion Channels

  2026-09-13

  Halazone connects rapid water disinfection with a precisely controlled neurophysiology perturbation model. This guide translates its HOCl-generating chemistry into practical microbiology, antimicrobial resistance research, and sodium-current workflows while separating validated findings from optimization recommendations.

• GnRH Antagonist Stereochemistry and Biological Activity

  2026-09-12

  Samant and colleagues examined how replacing position 3 of degarelix with stereochemically distinct 3-(2-methoxy-5-pyridyl)-alanine residues affected GnRH receptor antagonism and in vivo duration. The study shows that the D-configured analogue retained nanomolar in vitro activity, whereas the L-configured analogue was substantially weaker, yet both compounds were short-acting in rats.

• (-)-Norepinephrine (+)-bitartrate: Dose–Response Logic

  2026-09-11

  (-)-Norepinephrine (+)-bitartrate is more than a vasoconstrictor: it can function as a controlled adrenergic perturbation for linking receptor signaling to cardiovascular phenotype. This article explains how recent vascular-responsiveness research can improve assay design, dose interpretation, and translational cardiomyopathy studies.

• CHAP Model for Major Bleeding During Extended VTE Therapy

  2026-09-11

  This prospective multinational cohort study evaluated major bleeding risk during extended anticoagulation after unprovoked or weakly provoked venous thromboembolism. Modified ACCP, VTE-BLEED, and HAS-BLED scores identified higher-risk patients, while the simpler CHAP model used continuous creatinine, hemoglobin, and age measurements and showed comparable discrimination, although external validation remains necessary.

• SR-202: PPARγ Antagonist Workflow Guide

  2026-09-10

  SR-202 gives researchers a pharmacological way to test whether PPARγ signaling drives adipogenesis, macrophage polarization, and metabolic inflammation. This guide translates reference findings into practical cell-based and in vivo workflows, with formulation guidance, assay controls, and troubleshooting for insulin resistance research and obesity models.

• U0126-EtOH for Spatial ERK Assay Design

  2026-09-10

  Explore how U0126-EtOH, a selective MEK1/2 inhibitor, can turn MAPK/ERK pathway inhibition into a hypothesis-testing strategy for spatial patterning, neuronal oxidative stress, and inflammation research.

1127 records 7/76 page Previous Next First page 上5页 678910 下5页 Last page